{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:17:01Z","timestamp":1785799021076,"version":"3.56.0"},"reference-count":22,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pol J Pathol"],"abstract":"<jats:p>This research paper evaluates the\u00a0efficacy of\u00a0co-testing in precluding cervical cancer, with a\u00a0particular focus on distinguishable outcomes of\u00a0the\u00a0human papillomavirus (HPV) vs. cytology tests. &lt;br \/&gt;\nA\u00a0retrospective review of\u00a05948 patients, who tested positive for high-risk HPV but showed negative cytologic findings, revealed that 15.006% tested positive in subsequent screenings. &lt;br \/&gt;\nA\u00a0comparative analysis of\u00a0various commercial HPV tests highlighted the\u00a0precision of\u00a0mRNA-based HPV testing by Aptima (Hologic) in reducing the\u00a0likelihood of\u00a0false-negative cytology. &lt;br \/&gt;\nThe\u00a0paper challenges the\u00a0conviction that a\u00a0negative cytology alone suffices advocating for a\u00a0condensed testing interval in instances of\u00a0positive HPV outcomes, thereby facilitating earlier intervention and optimal preventive care. These findings unveil an exigency for reconsidering preventive strategies based on test outcomes.<\/jats:p>","DOI":"10.5114\/pjp.2024.135828","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T06:56:25Z","timestamp":1709794585000},"page":"36-39","source":"Crossref","is-referenced-by-count":3,"title":["Retrospective analysis of negative cytology results\ncorrelated with a positive high-risk in the human\npapillomavirus result and subsequent results\nof patients over a period of three years"],"prefix":"10.5114","volume":"75","author":[{"given":"Pawe\u0142 Gerard","family":"Piotrowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142 Teodor","family":"Jele\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3061","published-online":{"date-parts":[[2024,2,29]]},"reference":[{"key":"ref-1689870","unstructured":"Bruni L, Albero G, Serrano B, et al. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre).  Human Papillomavirus and Related Diseases in Poland. Summary Report 10 March 2023."},{"key":"ref-1689871","doi-asserted-by":"crossref","unstructured":"Baussano J, Bray F. Modelling cervical cancer elimination. Lancet Public Health 2019; 4: PE2-3.","DOI":"10.1016\/S2468-2667(18)30189-0"},{"key":"ref-1689872","doi-asserted-by":"crossref","unstructured":"Forman D, de Martel C, Lacey CJ. Global burden of\u00a0human papillomavirus and related diseases. Vaccine 2012; 30S: F12-23.","DOI":"10.1016\/j.vaccine.2012.07.055"},{"key":"ref-1689873","doi-asserted-by":"crossref","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.","DOI":"10.1016\/S0140-6736(07)61416-0"},{"key":"ref-1689874","doi-asserted-by":"crossref","unstructured":"Cuzick J, Clavel C, Petry KU. Overview of\u00a0the\u00a0European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101.","DOI":"10.1002\/ijc.21955"},{"key":"ref-1689875","doi-asserted-by":"crossref","unstructured":"Gissmann L, Wolnik L, Ikenberg H, et al. Human papillomavirus type 6 and 11 sequences in genital and laryngeal papillomas and some cervical cancers. Proc Natl Acad Sci USA 1983; 80: 560-563.","DOI":"10.1073\/pnas.80.2.560"},{"key":"ref-1689876","doi-asserted-by":"crossref","unstructured":"Zur Hausen H. Papillomaviruses in the\u00a0causation of\u00a0human cancers \u2013 a\u00a0brief historical account. Virology 2009; 384: 260-265.","DOI":"10.1016\/j.virol.2008.11.046"},{"key":"ref-1689877","unstructured":"Meisels A, Fortin R. Condylomatous lesions of\u00a0the\u00a0cervix and vagina.1. Cytologic patterns. Acta Cytol 1976; 20: 505-509."},{"key":"ref-1689878","doi-asserted-by":"crossref","unstructured":"Gasparini R, Panatto D. Cervical cancer: from Hippocrates through Rigoni-Stern to zur Hausen. Vaccine 2008; 27: A4-5.","DOI":"10.1016\/j.vaccine.2008.11.069"},{"key":"ref-1689879","doi-asserted-by":"crossref","unstructured":"Koliopoulos\u2008G, Nyaga\u2008VN, Santesso\u2008N, et al\u2008Cytology <i>versus<\/i> HPV testing for cervical cancer screening in the\u00a0general population. Cochrane Database Syst Rev\u20082017; 8: CD008587.","DOI":"10.1002\/14651858.CD008587.pub2"},{"key":"ref-1689880","doi-asserted-by":"crossref","unstructured":"Arbyn\u2008M, Ronco\u2008G, Anttila\u2008A, et al\u2008Evidence regarding human papillomavirus testing in secondary prevention of\u00a0cervical cancer. Vaccine\u20082012; 30: F88-99.","DOI":"10.1016\/j.vaccine.2012.06.095"},{"key":"ref-1689881","doi-asserted-by":"crossref","unstructured":"Melnikow\u2008J, Henderson\u2008JT, Burda\u2008BU, Senger\u2008CA, Durbin\u2008S, Weyrich\u2008MS.\u2008Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the\u00a0US Preventive Services Task Force. JAMA\u20082018; 320: 687-705.","DOI":"10.1001\/jama.2018.10400"},{"key":"ref-1689882","doi-asserted-by":"crossref","unstructured":"Wright\u2008TC, Stoler\u2008MH, Behrens\u2008CM, Sharma\u2008A, Zhang\u2008G, Wright\u2008TL.\u2008Primary cervical cancer screening with human papillomavirus: end of\u00a0study results from the\u00a0ATHENA study using HPV as the\u00a0first-line screening test. Gynecol Oncol\u20082015; 136: 189-197.","DOI":"10.1016\/j.ygyno.2014.11.076"},{"key":"ref-1689883","doi-asserted-by":"crossref","unstructured":"Xhaja A, Ahr A, Zeiser I, Ikenberg H. Two years of\u00a0cytology and HPV co-testing in Germany: initial experience. Geburtshilfe Frauenheilkd 2022; 82: 1378-1386.","DOI":"10.1055\/a-1886-3311"},{"key":"ref-1689884","doi-asserted-by":"crossref","unstructured":"Pankaj S, Kumari A, Kumari S, et al. Evaluation of\u00a0sensitivity and specificity of\u00a0Pap Smear, LBC and HPV in screening of\u00a0cervical cancer. Indian J Gynecol Oncolog 2018; 16: 49.","DOI":"10.1007\/s40944-018-0221-x"},{"key":"ref-1689885","unstructured":"Available from: https:\/\/www.nfz.gov.pl\/dla-pacjenta\/programy- profilaktyczne\/."},{"key":"ref-1689886","unstructured":"Wojciechowska U, Bara\u0144ska K, Micha\u0142ek I, Olasek P, Mikleska M, Didkowaska JA. Nowotwory z\u0142o\u015bliwe w\u00a0Polsce 2020 roku. Biuletyn Krajowego Rejestru Nowotwor\u00f3w, Warszawa 2022."},{"key":"ref-1689887","doi-asserted-by":"crossref","unstructured":"Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of\u00a0the\u00a0Papill<sup>o<\/sup>Check test, a\u00a0new commercial DNA chip for detection and genotyping of\u00a0human papillomavirus. J Virol Methods 2009; 156: 77-83.","DOI":"10.1016\/j.jviromet.2008.11.002"},{"key":"ref-1689888","doi-asserted-by":"crossref","unstructured":"You J, Croyle JL, Nishimura A, Ozato K, Howley PM. Interaction of\u00a0the\u00a0bovine papillomavirus E2 protein with Brd4 tethers the\u00a0viral DNA to host mitotic chromosomes. Cell 2004; 117: 349-360.","DOI":"10.1016\/S0092-8674(04)00402-7"},{"key":"ref-1689889","doi-asserted-by":"crossref","unstructured":"McBride AA, McPhillips MG, Oliveira JG. Brd4: tethering, segregation and beyond. Trends Microbiol 2004; 12: 527-579.","DOI":"10.1016\/j.tim.2004.10.002"},{"key":"ref-1689890","doi-asserted-by":"crossref","unstructured":"Pal A, Kundu R. Human papillomavirus E6 and E7: the\u00a0cervical cancer hallmarks and targets for therapy. Front Microbiol 2020; 10: 3116.","DOI":"10.3389\/fmicb.2019.03116"},{"key":"ref-1689891","unstructured":"Informacja Ministra Zdrowia w\u00a0sprawie w\u0142\u0105czenia do wykazu refundowanych lek\u00f3w szczepionki przeciw wirusowi brodawczaka ludzkiego (HPV) oraz zmian w\u00a0e-Karcie Szczepie\u0144. ZP\u015a.641.185.2021.JK.2, 29.10.2021 r."}],"container-title":["Polish Journal of Pathology"],"original-title":["Retrospektywna analiza wynik\u00f3w cytologii ujemnej skorelowanych z wynikami dodatnimi dla HR HPV i wynikami pacjent\u00f3w przez okres 3 lat."],"link":[{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-178483-136576","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.polishjournalofpathology.com\/pdf-178483-136576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:06:23Z","timestamp":1782212783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.polishjournalofpathology.com\/Retrospective-analysis-of-negative-cytology-results-r-ncorrelated-with-a-positive,178483,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["178483"],"URL":"https:\/\/doi.org\/10.5114\/pjp.2024.135828","relation":{},"ISSN":["1233-9687","2084-9869"],"issn-type":[{"value":"1233-9687","type":"print"},{"value":"2084-9869","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,29]]}}}